Articles published by NanoViricides, Inc.
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/9694.jpg?v=0)
![](https://storage.googleapis.com/accesswire/logos/share/2863.jpg?v=0)
NanoViricides Reports that It Has Begun Drug Development to Combat Recent Cases of Severe Pediatric Hepatitis
May 16, 2022
From NanoViricides, Inc.
Via AccessWire
Exposures
COVID-19
Tickers
NNVC
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/9694.jpg?v=0)
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/9694.jpg?v=0)
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/9694.jpg?v=0)
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/9694.jpg?v=0)
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/9694.jpg?v=0)
NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug Program Rapidly Moving Towards Clinical Stage
October 13, 2021
From NanoViricides, Inc.
Via AccessWire
Tickers
NNVC
![](https://storage.googleapis.com/accesswire/logos/subaccounts/share/9694.jpg?v=0)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.